Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Bucillamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Revive Expands Bucillamine Patents for Nerve Agents, Infections
    Revive Expands Bucillamine Patents for Nerve Agents, Infections

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/revive-therapeutics-strengthens-bucillamine-ip-portfolio-with-north-american-patent-filings-for-nerv

    PHARMIWEB
    11 Mar 2026
    Share Share
    Revive Therapeutics Updates Nerve Agent Countermeasure Study
    Revive Therapeutics Updates Nerve Agent Countermeasure Study

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205305/0/en/Revive-Therapeutics-Provides-Update-of-Key-Nerve-Agent-Countermeasure-Study.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Revive Therapeutics Updates Nerve Agent Countermeasure Study
    Revive Therapeutics Updates Nerve Agent Countermeasure Study

    21 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/21/3192926/0/en/Revive-Therapeutics-Provides-Update-of-Key-Nerve-Agent-Countermeasure-Study.html

    GLOBENEWSWIRE
    21 Nov 2025
    Share Share
    Revive Therapeutics Advances Bucillamine Development
    Revive Therapeutics Advances Bucillamine Development

    04 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/04/3093409/0/en/Revive-Therapeutics-Advances-with-Next-Generation-Bucillamine-Development.html

    GLOBENEWSWIRE
    04 Jun 2025
    Share Share
    Revive Therapeutics to Study Bucillamine for Cancer Treatment
    Revive Therapeutics to Study Bucillamine for Cancer Treatment

    10 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/10/3059109/0/en/Revive-Therapeutics-to-Investigate-Bucillamine-s-Potential-in-Cancer-Treatment.html

    GLOBENEWSWIRE
    10 Apr 2025
    Share Share
    Revive Updates R&D Focus on Bucillamine for Infectious Diseases
    Revive Updates R&D Focus on Bucillamine for Infectious Diseases

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019905/0/en/Revive-Therapeutics-Announces-Update-on-R-D-Focus-on-Bucillamine-for-Infectious-Diseases-and-Medical-Countermeasures.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.